Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target

Needham analyst Ami Fadia has reiterated a Buy rating on Acadia Pharmaceuticals (NASDAQ: ACAD) and maintained a price target of $35. This endorsement reflects confidence in the company's performance and potential in the market.